Wei Wu

Senior Associate

Wei is a scientist turned venture capitalist. She brings 10+ years of experience in research and venture investment covering life science tools, diagnostics, health-tech, and pharmaceuticals.


Prior to Illumina Ventures, Wei was the Director of Healthcare Investment and Business Development at BOE Ventures, the corporate venture arm of BOE Technology Group, where she focused on opportunities at the intersection of technology and life sciences. Investments led by Wei at BOE Ventures include Baebies, Ceribell, and life science VC funds. Wei was also the Co-chair of Biotech and Genomics investment committee of Life Science Angels, where she was instrumental in LSA seed investment in Mission Bio, Seal Rock Therapeutics, and Noctrix Health. Before being a venture capitalist, Wei was a R&D project lead at NuGEN Technologies (later acquired by TECAN to become TECAN Genomics).


As an enthusiast of university-based entrepreneurial ecosystem, Wei is an advisor of Stanford SPARK Translational Research Program and UC Berkeley SkyDeck Accelerator Biotrack including being a lead advisor of ThinkCyte and Cura Therapeutics.


Wei received B.S. in Biological Sciences from Beijing University, and Ph.D. in Biological Chemistry and Genetics from UCLA. She completed her postdoctoral training in Pathology at Stanford University School of Medicine.  She was trained by two National Academy of Sciences members and published in journals including Cell, Nature, Neuron, and Nature Reviews Genetics. She was a Bronze Medalist of the 12th International Biology Olympiad.

Copyright 2020 IIF Management Company LLC.  All rights reserved.  “Illumina” and “Illumina Ventures” are trademarks of Illumina, Inc. and are used herein with their permission.  All other company names, logos, and other trademarks are the property of their respective owners.